Chiesi Expands Its Rare Disease Reach With $1.48bn Amryt Buyout
US Expansion Also Part Of Strategy
The privately owned company currently earns most of its revenues in respiratory medicine in Europe, but has set its sights on expanding in rare diseases and the US market.
You may also be interested in...
Chiesi-owned Amryt and Krystal Biotech have approved treatments for epidermolysis bullosa but Paradigm CEO Robert Ryan tells Scrip that SD-101, a topical cream he helped develop over 20 years ago, has the potential to be offer a far more extensive and efficacious solution for many more sufferers.
With an EU submission imminent for its MCT8 deficiency therapy Emcitate, Egetis is in talks with “certain external partners” about an acquisition.
The Irish biotech has launched a Phase IIb/III trial of its sphingosine 1 phosphate receptor modulator mocravimod, expanding a mode of action that has been successful in autoimmune indications into the hematology space.